Indirect Treatment Comparison of Venetoclax plus Rituximab with B-cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia

被引：0
|
作者：
Mato, A. [1 ]
Follows, G. [2 ]
Sail, K. [3 ]
Diakite, I. [4 ]
Nicoloso, D. [4 ]
Dietz, B. [5 ]
Maher, J. [6 ]
Alexiou, D. [6 ]
Chirikov, V. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Haematol, Cambridge, England
[3] AbbVie Inc, N Chicago, IL USA
[4] Pharmerit Int, Bethesda, MD USA
[5] AbbVie Deutschland GmbH & Ko KG, Ludwigshafen, Germany
[6] AbbVie, N Chicago, IL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [41] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [42] Another treatment option for relapsed or refractory chronic lymphocytic leukaemia
    Mauro, Francesca R.
    LANCET ONCOLOGY, 2017, 18 (03): : 270 - 271
  • [43] Venetoclax Management and care for patients with relapsed or refractory chronic lymphocytic leukemia
    Paradis, Heather Brumbaugh
    Alter, Debbie
    Lterandi, Diane
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (05) : 604 - 610
  • [44] IMPACT OF ADDING RITUXIMAB TO VENETOCLAX ON THE RATE, QUALITY, AND DURATION OF RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA: A CROSS-STUDY MULTIVARIABLE ANALYSIS
    Roberts, A. W.
    Ma, S.
    Brander, D.
    Kipps, T. J.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Choi, M.
    Tam, C.
    Lash, L. L.
    Verdugo, M.
    Kim, S. Y.
    Zhu, M.
    Seymour, J. F.
    HAEMATOLOGICA, 2016, 101 : 51 - 52
  • [45] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
    Arcari, Annalisa
    Chiappella, Annalisa
    Valenti, Vanessa
    Zanlari, Luca
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Spina, Michele
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Della Seta, Roberta
    Vallisa, Daniele
    BLOOD, 2014, 124 (21)
  • [46] BENDAMUSTINE MONOTHERAPY IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
    Lucania, A.
    Esposito, M.
    Della Cioppa, P.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 74 - 74
  • [47] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [48] Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia
    Eskelund, Christian W.
    Nederby, Line
    Thysen, Anna H.
    Skovbo, Anni
    Roug, Anne S.
    Hokland, Marianne E.
    LEUKEMIA RESEARCH, 2011, 35 (07) : 914 - 920
  • [49] Microsatellite instability in patients with chronic B-cell lymphocytic leukaemia
    E Niv
    Y Bomstein
    M Yuklea
    M Lishner
    British Journal of Cancer, 2005, 92 : 1517 - 1523
  • [50] Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
    Huhn, D
    von Schilling, C
    Wilhelm, M
    Ho, AD
    Hallek, M
    Kuse, R
    Knauf, W
    Riedel, U
    Hinke, A
    Srock, S
    Serke, S
    Peschel, C
    Emmerich, B
    BLOOD, 2001, 98 (05) : 1326 - 1331
12345